Search results
Results From The WOW.Com Content Network
The world's largest drugmaker's profit tumbled 19 percent, although it slightly exceeded analysts' estimates. Revenue was largely impacted by unfavorable Pfizer tops estimates, but challenges remain
This list has all global annual earnings of all time, limited to earnings of more than $40 billion in "real" (i.e. CPI adjusted) value. Note that some record earning may be caused by nonrecurring revenue, like Vodafone in 2014 (disposal of its interest in Verizon Wireless) [1] or Fannie Mae in 2013 (benefit for federal income taxes).
Margins matter. The more Pfizer (NYS: PFE) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
As investors, we need to understand how our companies truly make their money. A neat trick developed for just that purpose -- the DuPont formula -- can help us do so. So in this series we let the ...
A company's earnings before interest, taxes, depreciation, and amortization (commonly abbreviated EBITDA, [1] pronounced / ˈ iː b ɪ t d ɑː,-b ə-, ˈ ɛ-/ [2]) is a measure of a company's profitability of the operating business only, thus before any effects of indebtedness, state-mandated payments, and costs required to maintain its asset base.
The 10-second takeaway For the quarter ended Dec. 31 (Q4), Pfizer beat expectations on revenues and beat expectations on earnings per share. Compared to the Pfizer Beats on Both Top and Bottom Lines
On October 12, 2010, Pfizer Inc. (NYSE: PFE) announced it would acquire Bristol-based King Pharmaceuticals, Inc. for a total cost to Pfizer of $3.6 billion in cash or $14.25 per share. The acquisition was expected to expand Pfizer's product line of pain relief and management medication by adding King products such as Embeda, Avinza, and the ...